Roche's Flatiron Health Expands Global Oncology Network, Triples Reach Across UK, Germany, and Japan

Flatiron Health, a subsidiary of pharmaceutical giant Roche, has announced a significant expansion of its international oncology network, tripling its size across the United Kingdom, Germany, and Japan over the past year. This growth marks a pivotal step in the company's mission to provide comprehensive real-world cancer data on a global scale.

Network Expansion and Strategic Partnerships

The New York-based health technology company has extended its reach to include 30 institutions across Europe and Asia. Notable additions to the network include Leeds Teaching Hospitals NHS Trust in the UK, Klinikum Stuttgart in Germany, and the National Cancer Center Hospital in Japan. This expansion is aimed at addressing the critical need for real-world oncology data, which is often scarce in cancer research and treatment development.

Nathan Hubbard, Flatiron Health's chief business officer, emphasized the significance of this growth, stating, "The unprecedented expansion of our global network will continue to support improvements to local cancer patients' care and novel multinational research—fundamentally changing what's possible for our partners and the patients they serve."

Flatiron FORUM: Fostering International Collaboration

In conjunction with its network expansion, Flatiron Health has established the Flatiron FORUM, a consortium of academic and biopharmaceutical partners. This initiative is designed to conduct research studies that examine the transferability of conclusions drawn from real-world cancer evidence across national borders. The FORUM represents a strategic move to enhance the global applicability of oncology insights and foster international collaboration in cancer research.

Enhancing Clinical Trial Recruitment

While expanding its global footprint, Flatiron Health is also strengthening its operations within the United States. The company has recently formed a partnership with Massive Bio to utilize their patient database for identifying and recruiting participants for clinical trials. This collaboration aims to connect patients living near clinical trial sites with research opportunities within Flatiron's network, potentially accelerating the pace of cancer research and drug development.